文献速递脊柱关节炎

基线体重指数对托法替布治疗银屑病关节炎疗效与安全性的影响

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
PubMed 文献 · RMD Open · 2021-01-01

该事后分析汇总两项3期研究共710例活动性银屑病关节炎患者,按基线BMI分层比较托法替布5/10 mg每日两次与安慰剂的疗效和安全性。结果显示无论BMI如何托法替布疗效均优于安慰剂,但基线BMI≥35 kg/m²者疗效普遍降低,安全性总体可比。

要点

  • 无论基线BMI如何,托法替布第3个月疗效反应率均高于安慰剂。
  • 基线BMI≥35 kg/m²患者ACR20/50/70、HAQ-DI等应答普遍降低。
  • 基线BMI≥35 kg/m²者托法替布5 mg每日两次出现转氨酶升高,10 mg未见。

核心结论

  • 托法替布在活动性银屑病关节炎患者中疗效优于安慰剂,且不受基线BMI影响;但基线BMI≥35 kg/m²者各治疗组疗效均降低,安全性总体可比。

研究设计与样本

  • 事后分析,汇总两项3期研究(NCT01877668;NCT01882439)数据,共纳入710例随机接受托法替布5/10 mg每日两次或安慰剂的患者,按基线BMI分层。

主要发现

  • 第3个月托法替布各BMI亚组ACR20/50/70、HAQ-DI、PASI75应答率及指炎/附着点炎消退率高于安慰剂。
  • 基线BMI≥35 kg/m²者ACR20/50/70、HAQ-DI应答率、附着点炎消退率及SF-36v2 PCS和FACIT-F总分改善普遍低于较低BMI者。
  • 基线BMI≥35 kg/m²接受托法替布5 mg每日两次者报告ALT/AST升高,10 mg每日两次未见。
  • 安全性在各BMI类别间总体可比,但BMI≥35 kg/m²者肝酶影响结论不确定。

关键数值与推荐

  • 共710例患者,43.8%为肥胖(BMI≥30 kg/m²)。
  • BMI分层:<25、≥25-<30、≥30-<35、≥35 kg/m²。
  • 终点为第3个月ACR20/50/70、HAQ-DI、PASI75应答率,指炎/附着点炎消退率,SF-36v2 PCS及FACIT-F总分变化。

临床怎么用

  • 对基线BMI≥35 kg/m²的银屑病关节炎患者,托法替布仍优于安慰剂但应答可能降低,需加强疗效监测。
  • BMI≥35 kg/m²使用托法替布5 mg每日两次时注意监测转氨酶。

局限性

  • 为事后分析,结果需前瞻性研究验证;肝酶影响结论不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This post-hoc analysis explored the impact of body mass index (BMI) on tofacitinib efficacy/safety in patients with active psoriatic arthritis (PsA). METHODS: Data were pooled from two phase 3 studies (NCT01877668; NCT01882439). Analyses included patients randomised to tofacitinib 5/10 mg twio times a day or placebo, stratified by baseline BMI: <25 kg/m2, ≥25-<30 kg/m2, ≥30-<35 kg/m2 or ≥35 kg/m2. Endpoints (month 3): American College of Rheumatology (ACR20/50/70), Health Assessment Questionnaire-Disability Index (HAQ-DI) and Psoriasis Area and Severity Index (PASI) 75 response rates; dactylitis/enthesitis resolution rates; changes from baseline Short Form-36 Health Survey version 2 (SF-36v2) Physical/Mental Component Summary (PCS) scores and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score. Safety was also reported. RESULTS: Analysis included 710 patients; 43.8% were obese (BMI ≥30 kg/m2). Tofacitinib demonstrated higher efficacy response rates at month 3, compared with placebo, regardless of baseline BMI. Generally, ACR20/50/70 and HAQ-DI response rates, enthesitis resolution rates and changes from baseline in SF-36v2 PCS score and FACIT-F total score (month 3) were reduced in patients with baseline BMI ≥35 kg/m2 versus patients with lower BMIs. Elevated alanine aminotransferase/aspartate aminotransferase levels were reported in patients with baseline BMI ≥35 kg/m2 receiving tofacitinib 5 mg but not 10 mg two times a day. CONCLUSION: Tofacitinib demonstrated greater efficacy than placebo in patients with PsA, regardless of baseline BMI. For all treatment arms, reduced efficacy was observed in patients with baseline BMI ≥35 kg/m2. Safety was generally comparable across BMI categories, although the effect of tofacitinib on liver enzymes in patients with baseline BMI ≥35 kg/m2 was inconclusive.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Giles JT, Ogdie A, Gomez Reino JJ, et al. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD Open. 2021. PMID: 33452181. doi:10.1136/rmdopen-2020-001486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。